Download Curriculum Vitae

Curriculum Vitae
Prof. Renata Stripecke, PhD
1. Personal Information
Name/ Title
Renata Stripecke, Prof. Dr. rer. nat. hab.
Birth Date/ Place
May 4, 1965/ Sao Paulo, Brazil
Nationalities
Germany, USA, Brazil
Children
Languages
2
Native: Portuguese; fluent: English, German and Spanish
Work Address Laboratory of Regenerative Immune Therapies Applied/ REBIRTH
Department of Hematology Hemostasis, Oncology and Stem Cell
Transplantation - Hannover Medical School
Carl-Neuberg-Strasse 1 - OE6860, Hans Borst Zentrum/ r. 6100
30625 Hannover, Germany
Phone
++49/511 532 6999 / FAX: ++49/511 532 6975
Work Email
[email protected]
Web Pages
www.stripecke-mhh.de
http://www.rebirth-hannover.de/de/research/research-groups/area-b/unit-6-4.html
http://www.rebirth-hannover.de/en/phd-program/rebirth-ambassadors.html
http://www.sfb738.de/teilprojekt-a6.html
2. Education
1983-86
UNICAMP - State University of Campinas (Campinas, SP, Brazil);
Bachellor’s Degree and Licenciate in Biological Sciences.
1986-88
UNICAMP - State University of Campinas (Campinas, SP, Brazil): Master’s
Degree in Genetics. Topic: genetic engineering of bacteria.
1988-89
Ludwig-Maximilians-University (Munich, Germany): PhD Fellow, KonradAdenauer Stiftung at the Institute for Genetics and Microbiology. Topic: genetic
recombination in bacteriophages and bacteria.
1990-94
European Molecular Biology Laboratory (Heidelberg, Germany): PhD
completed (magna cum lauda). in Gene Expression with Prof. Dr. Matthias
Hentze. Topic: post-transcriptional gene regulation.
2000-02
University Hamburg (Hamburg, Germany): DFG Habilitation fellow in
Genetics and Molecular Biology, (with Prof. Dr. Wolfram Ostertag). Topic: gene
therapy and leukemia immunotherapy.
R. Stripecke, CV
3. Post-doctoral Training
1994-96
UCLA - University of California, Los Angeles (Los Angeles, CA, USA):
DFG post-doctoral fellow (with Prof. Dr. Larry Simpson HHMI). Topic: RNAediting.
1996-99
USC - University of Southern California (Los Angeles, CA, USA): Research
Associate at Childrens Hospital Los Angeles (with Prof. Dr. Donald Kohn).
Topic: gene therapy, leukemia immunotherapy.
4. Academic Appointments
1999-2003
Assistant Professor of Research: Dept. Pathology, School of Medicine,
University of Southern California, Los Angeles, CA, USA.
2003-07
Adjunct Assistant Professor: Dept. Medicine/ School of Medicine, University
of California, Los Angeles, CA, USA.
2007-08
Group Leader in Lymphatic Cell Therapy: DFG-Excellence Cluster
REBIRTH, Hannover Medical School, Hannover, Germany.
2008-13
W2 Associate Professor “Lymphatic Cell Therapy” in Tenure Track: at the
Dept. Hematology, Hemostasis, Oncology, and Stem Cell Transplantation and
Excellence Cluster Rebirth, Hannover Medical School, Hannover, Germany.
2008
Faculty Member of the MHH Hannover Biomedical Research School in the
structured PhD programs “Molecular Medicine”,” Regenerative Sciences” and
“Infectious Biology”.
2012-
Vice-chair of the Regenerative Sciences PhD program at the MHH.
03. 2013-
Tenure track evaluation successfully completed for W2 Associate
Professor “Regenerative Immune Therapies Applied”: at the Dept.
Hematology, Hemostasis, Oncology, and Stem Cell Transplantation and
Excellence Cluster Rebirth, Hannover Medical School, Hannover, Germany.
5. Other Professional Activities
2001-02
IntraGene Sciences, Inc., Director of Cell Engineering, Pasadena, CA, USA.
2003-07
UCLA Molecular Vector Core, Co-director / Dept. Medicine/ School of
Medicine, University of California, Los Angeles, CA, USA.
6. International Awards
1985-86
FAPESP Scientific Initiation Fellowship (Brazil).
1987-88
CAPES/CNPq Masters’ Degree Fellowship (Brazil).
1988-90
Konrad Adenauer Stiftung PhD Scholarship (Germany).
1990-94
CAPES/CNPq and EMBL PhD Scholarships (Brazil/ EMBL).
1994-95
DFG Post-doctoral Scholarship (Germany).
1994
Alexander von Humboldt Post-doctoral Scholarship (Germany) (awarded but
not taken).
1997-98
Childrens Hospital Los Angeles Career Award (USA)
1
R. Stripecke, CV
1999-02
Leukemia and Lymphoma Society Special Fellow Award (USA).
2000-03
National Cancer Institute/NIH K01/ Howard Temin Award (USA).
2001-02
DFG Habilitation Scholarship (Germany).
2002-05
Stop Cancer/ USC and UCLA Career Development Award (USA).
2003-06
Cure/UCLA Career Development Award (USA).
7. Patents
R. Stripecke, G. Salguero, A. Daenthasanmak, A. Ganser. “Induced dendritic cells and uses thereof”
(PCT/EP2013/052485). Priority date 07 February 2013; International Filing Date 24 January
2014; Published August 14 2014.
8. Membership in National and International Scientific Societies
1997- :
American Society of Gene and Cell Therapy (ASGCT, USA). Scientific
Committee Member for “Immune responses to Gene and Cell Therapy”.
2001- :
American Society of Hematology (ASH, USA).
2000- :
Deutsche Gesellschaft für Gentherapie (DG-GT, Germany).
2007- :
European Society for Cell and Gene Therapy (ESCGT, Europe).
2010-:
Helmholtz Alliance on Immunotherapy of Cancer (HAIT, Germany)
2012-:
International Society of Gene and Cell Therapy (ISGCT).
2012-:
International Society of Experimental Hematology (ISEH).
9. Scientific Advisory Board for
Journals: Human Gene Therapy Methods, Human Gene Therapy Clinical Development
Societies: American Society of Gene and Cell Therapy- Immune responses to Gene and Cell
Therapy Committee; American Society of Gene and Cell Therapy- International Committee.
10. Peer Reviewer for Journals (in alphabetical order, selected)
Annals of Hematology, Blood, Experimental Hematology, Gene Therapy, Human Gene
Therapy, Leukemia, Journal of Gene Medicine, Journal of General Virology, Journal of
Translational Medicine, Molecular Therapy.
11. Scientific Reviewer for Agencies and Committees
1998-
The Concern Foundation Los Angeles, CA, USA.
2004-
German Research Council (DFG) Germany.
2004-07
Jonsson Comprehensive Cancer Center (UCLA) Los Angeles, CA, USA.
2005- 07
Human Gene Medicine Program (UCLA) Los Angeles, CA, USA.
2005- 07
Cedars Sinai Los Angeles, CA, USA.
2008-
Deutsche Krebshilfe Germany.
2008-
BayImmuNet Bavaria, Germany.
2011-:
Fonds Wetenschappelijk Onderzoek (FWO), Belgium.
2012-
Landsteiner Foundation for Blood Transfusion Research, Netherlands.
2
R. Stripecke, CV
2012-
Asociation Fraincaise contre les Myopathies AFM, France.
2012-
Fundacao a Ciencia e Tecnologia, Portugal.
2012-
Fund for Scientific Research, Belgium.
2013-
Life Sciences and Health, Translational Adult Stem Cell Research,
Netherlands.
2013-
Deutscher Akademischer Austauschdienst (DAAD), Germany.
2013-
Life
Sciences
and
Health,
Impuls
programme
for
public-private
partnership, Netherlands.
12. Peer-reviewed publications (selected)
1.
Stripecke, R. and Hentze, M.W. (1992). Bacteriophage and spliceosomal proteins function as
position-dependent cis-trans repressors of mRNA translation in vitro. Nucl Acids. Res, 20(21):
5555-64. IF 7.479
2.
Boelens,W.C., Jansen, E.J.R., van Venrooij, W.J., Stripecke, R., Mattaj, I.W. and Gunderson,
S.I. (1993). The human U1 snRNP-specific U1A protein inhibits polyadenylation of its own premRNA. Cell, 72: 881-92. IF 31.152
3.
Oliveira, C.C., Goossen, B., Zanchin, N.I.T., McCarthy, J.E.G., Hentze, M.W. & Stripecke, R.
(1993). Translational repression by the human iron-regulatory factor (IRF) in Saccharomyces
cerevisiae. Nucl Acids Res, 21(23): 5316-22. IF 7.479
4.
Stripecke, R., Oliveira, C.C, McCarthy, J.E.G. and Hentze, M.W. (1994). Proteins Binding to
5’UTR sites: A general mechanism for translational regulation of mRNAs in mammalian and
yeast cells Mol Cell Biol, 14(9): 5898-5909.IF 6.057
5.
Muckenthaler, M., Gunkel, N., Stripecke, R. and Hentze, M.W. (1997). Regulated poly(A) tail
shortening in somatic cells mediated by cap-proximal translational repressor proteins and
ribosome association. RNA, 3: 983-995. IF 5.198
6.
Stripecke, R., Skelton, D., Gruber, T., Afar, D., Witte, O.N. and Kohn, D.B. (1998). Immune
response to Philadelphia chromosome positive Acute Lymphoblastic Leukemia induced by
CD80, IL-2 and GM-CSF. Hum Gene Ther, 9 (14): 2049-2062. IF 4.202
7.
Case, S.S, Price, M.A., Jordan, C.T., Xu, D., Bauer, G., JinYu, X., Stripecke, R., Naldini, L.,
Kohn, D.B, and Crooks, G.M (1999). Stable transduction of quiescent CD34+CD38- human
hematopoietic cells by HIV-based lentiviral vectors. Proc Nat Acad Scien USA, 96: 2988-2933.
IF 9.432
8.
Stripecke, R., Villacres, M.C, Skelton, D.C., Satake, N., Halene, S. and Kohn, D.B. (1999)
Immune responses against enhanced green fluorescent protein: implications for gene therapy.
Gene Ther, 6(7):1305-1312. IF 4.745
9.
Stripecke, R., Skelton, D.C., Shimada, H., Pattengale, P. and Kohn, D.B. (1999). Combination
of CD80 and GM-CSF co-expression by a leukemia cell vaccine: pre-clinical studies in a murine
model recapitulating Philadelphia chromosome positive Acute Lymphoblastic Leukemia in mice.
Hum Gene Ther, 10:2118-2122. IF 4.202
10.
Stripecke, R., Cardoso, A. Pepper, K.A., Skelton, D.C., Xu, X.-J., Mascarenhas, L., Weinberg,
K.I., Nadler, L.M. and Kohn, D.B. (2000). Lentiviral vectors for efficient gene delivery and
expression of CD80 and granulocyte-macrophage-colony stimulating factor in human acute
lymphoblastic leukemia and acute myeloid leukemia cells to induce anti-leukemia immune
responses. Blood, 96: 1417-1326. IF 10.555
11.
Koya R.C., Kasahara N., Pullarkat V., Levine A.M. and Stripecke R. (2002). Transduction of
acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing
3
R. Stripecke, CV
CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and
autologous anti-leukemia immune responses. Leukemia, 16 (9): 1645-1654.IF 8.296
12.
Koya, RC, Weber JS, Kasahara, N, Lau, R, Levine, AM and Stripecke, R. (2004). Making
Dendritic Cells from Inside-Out: lentiviral vector-mediated gene delivery of GM-CSF and IL-4
into CD14+ monocytes generates DCs in vitro. Hum Gene Ther, 15:733-48. IF 4.202
13.
Koya R., Kimura T., Ribas A., Rozengurt N., Lawson GW, Faure-Kumar E., Wang H-J,
Herschmann H., Kasahara K. and Stripecke R (2007). Lentiviral vector-mediated autonomous
differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Mol Ther, 15(5):971-80 IF 6.239
14.
Kimura T., Koya RC., Anselmi L, Sternini C., Wang H., Comin-Anduix B., Prins R., FaureKumar E., Cui Y., Rozengurt N., Kasahara N. and Stripecke R (2007). Lentiviral Vectors with
CMV or MHCII Promoters administered in vivo: Immune reactivity versus persistence of
expression. Mol Ther, 15(7):1390-9. IF 6.239
15.
Jirmo AC, Koya RC, Sundarassety BS, Pincha M, Yu G-Y, Lai M, Bakshi R, Schlaphoff V,
Grabowski J, Behrens G, Wedemeyer H, Stripecke R (2010). Monocytes Transduced with
Lentiviral Vectors Expressing Hepatitis C Virus Non-Structural Proteins and Differentiated into
+
Dendritic Cells Stimulate Multi-antigenic CD8 T cell responses. Vaccine, 28(4):922-33. IF
3.616
16.
Pincha M, Salguero G, Wedekind D, Sundarasetty BS, Lin A, Kasahara N, Brugman MH, Jirmo
AC, Modlich U, Gutzmer R, Büsche G, Ganser A, Stripecke R (2011). Lentiviral vectors for
induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther, 18(8):75064. IF 4.745
17.
Rickmann M ; Krauter J, Stamer K, Heuser M, Salguero G, Mischak-Weissinger E, Ganser A,
Stripecke R (2011). Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells
in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol, 90(9):104758.IF 2.919
18.
Salguero G, Sundarasetty BS, Borchers S, Wedekind D , Eiz-Vesper B, Velaga S, Jirmo AC,
Behrens G, Warnecke G, Knöfel AK, Blasczyk R, Mischak-Weissinger E, Ganser A, Stripecke
R (2011). Pre-conditioning therapy with lentiviral vector-programmed dendritic cells accelerates
the homeostatic expansion of antigen-reactive human T cells in NOD.Rag -/-.IL-2rγc -/- mice.
Hum Gene Ther, 22(10):1209-24. IF 4.202
19.
Pincha M, Sundarasetty BS, Salguero G, Ralf Gutzmer, Henk Garritsen, Laura Macke, Andreas
Schneider, Daniela Lenz, Figueiredo C, Blasczyk R, Ruggiero E, Schmidt M, von Kalle C, Puff
C, Modlich U, von der Leyen H, Wicke DC, Ganser A, Stripecke R (2012). Identity, Potency, In
Vivo Viability, and Scaling Up Production of Lentiviral Vector-Induced Dendritic Cells for
Melanoma Immunotherapy. Hum Gene Ther Meth, 23(1):38-55. IF- (NA)
20.
Daenthanasanmak A, Salguero G, Borchers S, Figueiredo C, Jacobs R, Sundarasetty BS,
Schneider A, Schambach A, Eiz-Vesper B, Blasczyk R, Weissinger EM, Ganser A, Stripecke R
(2012). Integrase-defective Lentiviral Vectors Encoding Cytokines Induce Differentiation of
Human Dendritic Cells and Stimulate Multivalent Immune Responses in vitro and in vivo.
Vaccine, 30(34):5118-31 IF 3.616
21.
Sundarasetty BS, Singh VK, Salguero G, Geffers R, Rickmann M, Macke L, Borchers S,
Figueiredo C, Schambach A, Gullberg U, Provasi E, Bonini C, Ganser A, Woelfel T, Stripecke
R. (2013). Lentivirus-induced dendritic cells for active and long-lasting immunization against
+
high-risk WT1 acute myeloid leukemia. Hum Gene Ther, 24(2):220-37. IF 4.202
22.
Rickmann M, Macke L, Sundarasetty BS, Stamer K, Figueiredo C, Blasczyk R, Heuser M,
Krauter J, Ganser A, Stripecke R. (2013) Monitoring dendritic cell and cytokine biomarkers
during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Ann
Hematol.;92(8):1079-90. IF 2.919
4
R. Stripecke, CV
23.
Gustavo Salguero, Anusara Daenthasanmak, Christian Münz, Ana Raykova, Carlos A.
Guzmán, Peggy Riese, Constanca Figueiredo, Florian Länger, Andreas Schneider, Laura
Macke, Bala Sai Sundarasetty, Torsten Witte, Arnold Ganser, Renata Stripecke. Dendritic CellMediated Immune-Humanization of Mice: Implications for allogeneic and xenogeneic stem cell
transplantation. Journal of Immunology, May 15;192(10):4636-47.
24.
Daenthanasanmak A, G Salguero, B Sundarasetty, C Waskow, K Nehir Cosgun, C Guzman,
P Riese, L Macke, A Schneider, A Ingendoh, M Messerle, I Gabaev, B Woelk, E
Ruggiero, M Schmidt, C von Kalle, C Figueiredo, B Eiz-Vesper, C von Kaisenberg, A
Ganser and R Stripecke. Engineered dendritic cells from cord blood and adult blood accelerate
effector T cell immune reconstitution against HCMV. Molecular Therapy Methods and Clinical
Development (in press).
5